Analyzing blood flow in the whole body using a special PET/CT scan
The Application of Total-body 13N-NH3 PET/CT to Study the Blood Perfusion System in the Whole Body
This study is testing a special scan to see how blood flow in the body is affected in people with heart problems compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 60 Years to 90 Years |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT04941248 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze and quantify whole-body blood perfusion using total-body 13N-NH3 PET/CT scans. It will involve 25 participants, including 16 patients diagnosed with decreased cardiac function and 9 healthy individuals for comparison. Participants will undergo a screening process, receive a dose of a radioactive tracer, and then have a total body PET/CT scan to assess blood flow in various organs. The goal is to understand how decreased cardiac function affects blood perfusion throughout the body.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 60-90 with decreased cardiac function or healthy volunteers with normal heart function.
Not a fit: Patients with severe liver or kidney dysfunction, or those with a history of vascular-related diseases in other organs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effects of decreased cardiac function on blood flow, potentially leading to improved management of cardiac conditions.
How similar studies have performed: While this approach is innovative, similar studies using PET/CT for blood perfusion analysis have shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Nine healthy volunteers with normal EF values * Patients with decreased cardiac function, while their heart function grading above II(New York Heart Association,NYHA) * Aged 60\~90 years old * Written informed consents will be offered and signed by all participants Exclusion Criteria: * History of vascular-related diseases in other organs * Severe liver and kidney dysfunctions * Patients who are pregnant or breast feeding * People under the age of 60 years old * Heart function grading below II(NYHA) * inability to lie or to maintain posture in the scanner for one hour
Where this trial is running
Shanghai, Shanghai
- Shanghai jiaotong University School of Medicine, Renji Hospital — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Yumei Chen, Ph.D; M.D. — Shanghai Jiaotong University School of Medicine,Renji Hospital
- Study coordinator: Yumei Chen, Ph.D; M.D.
- Email: cymrenji@126.com
- Phone: 86-021-58752345
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.